| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy. |
|
Medicine details |
|
| Medicine name | ramucirumab (Cyramza®) |
| Formulation | 10 mg/ml concentrate for solution for infusion |
| Reference number | 2376 |
| Indication | In combination with paclitaxel for treatment of patients with advanced gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma after failure of prior fluropyrimidine and platinum-based chemotherapy. As a monotherapy for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/01/2015 |
| NICE guidance | |